The interactions of paclitaxel with tumour microenvironment.

Ding-Li Yu, Zhi-Ping Lou, Feng-Yun Ma, Masoud Najafi

International immunopharmacology 2022 Apr

filter terms:

Today, it is well-known that the interactions and secretion within the tumour are crucial to consider for cancer therapy. Some novel cancer therapy modalities such as immunotherapy or tumour vaccination therapy work based on the control of interactions within the tumour microenvironment (TME). It has been revealed that anti-cancer drugs or radiotherapy can modulate some interactions in favour of cancer therapy. However, they may induce some mechanisms to increase the resistance of cancer cells to therapy. Paclitaxel is known as the first approved herbal derived chemotherapy drug. Although the main known anti-cancer effect of paclitaxel is the inhibition of the cell cycle, today, it has been well known that paclitaxel may suppress the tumour via modulating several interactions in TME. Furthermore, paclitaxel may increase the expression of some tumour resistance drivers. This review aims to discuss the interactions within TME following treatment with paclitaxel. The effects of paclitaxel on the anti-tumour immunity, immunosuppressive cells, hypoxia, and also angiogenesis will be discussed. The targeting of these interactions may be interesting to increase therapy efficiency using the combination modalities. Copyright © 2022 Elsevier B.V. All rights reserved.

Citation

Ding-Li Yu, Zhi-Ping Lou, Feng-Yun Ma, Masoud Najafi. The interactions of paclitaxel with tumour microenvironment. International immunopharmacology. 2022 Apr;105:108555